Crossmark

Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy

Crossref DOI link: https://doi.org/10.1186/s40425-019-0725-7

Published Online: 2019-09-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shi, Jing

Chen, Chen

Ju, Rui

Wang, Qingzhu

Li, Juan

Guo, Lei https://orcid.org/0000-0001-9060-3988
Ye, Caiying

Zhang, Dechang
Funding

Funding for this research was provided by:

National Science Foundation of China (81872897)

National Science Foundation of China (81402943, 81672966,)

CAMS Major Collaborative Innovation Project (2016-I2M-1-011)
License Information

Text and Data Mining valid from 2019-09-11
More Information

Article History

Received: 4 May 2019

Accepted: 30 August 2019

First Online: 11 September 2019

Ethics approval and consent to participate

: All animal studies and procedures were approved by the Institutional Animal Care and Use Committee of Peking Union Medical College (registration number: ACUC-A02–2017-013).

: Not applicable

: The authors declare that they have no competing interests.